Evaluation of the safety and efficacy of micafungin in Japanese patients with deep mycosis: A post-marketing survey report

Journal of Infection and Chemotherapy

Volumn 17, Issue 5, 2011, Pages 622-632

  Hanadate, Tomoko ^a   Wakasugi, Masahiro ^a   Sogabe, Keizo ^a   Kobayashi, Toshimitsu ^a   Horita, Hisanori ^a   Kawamura, Ikuo ^a   Hori, Yasuhiro ^a   Matsui, Keita ^a   Hoshino, Yo ^a   Sou, Masahiro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Fungal infection; Micafungin; Post marketing survey

Indexed keywords

MICAFUNGIN;

ADOLESCENT; ADULT; AGED; ANEMIA; APPLICATION SITE REACTION; ARTICLE; ASPERGILLUS; BLADDER DISEASE; CANDIDIASIS; CAUSAL ATTRIBUTION; CLINICAL ASSESSMENT; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; EOSINOPHILIA; EYE DISEASE; EYELID EDEMA; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOPATHOLOGY; INFECTION; INFESTATION; INJURY; JAPANESE; KIDNEY DISEASE; LABORATORY TEST; LIVER DYSFUNCTION; LYMPHATIC SYSTEM DISEASE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MYCOSIS; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; POSTMARKETING SURVEILLANCE; PROSPECTIVE STUDY; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE; THORAX DISEASE; THROMBOCYTOPENIA; THROMBOCYTOSIS; TREATMENT DURATION; VASCULAR DISEASE;

EID: 84855421044     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-011-0219-0     Document Type: Article

References (26)

1. Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis. 2002;15(6):569-74. (Pubitemid 36026968)
2. Kume H, Yamazaki T, Abe M, Tanuma H, Okudaira M, Okayasu I. Epidemiology of visceral mycoses in patients with leukemia and MDS: Analysis of the data of annual pathological autopsy cases in Japan in 1989, 1993, 1997 and 2001. Jpn J Med Mycol. 2006;47(1):15-24.
3. Brahm H, Segal BH. Aspergillosis. N Engl J Med. 2009;360: 1870-84.
4. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-35.
5. Gafter-Gvili A, Vidal L, Goldberg E, Leibovici L, Paul M. Treatment of invasive candidal infections: Systematic review and meta-analysis. Mayo Clin Proc. 2008;83(9):1011-21.
6. Jarvis B, Figgitt DP, Scott LJ. Micafungin. Drugs. 2004;64(9): 969-82. (Pubitemid 38608475)
7. Chandrasekar PH, Sobel JD. Micafungin: A new echinocandin. Clin Infect Dis. 2006;42:1171-8.
8. Ikeda F, Tanaka S, Ohki H, Matsumoto S, Maki K, Katashima M, et al. Role of micafungin in the antifungal armamentarium. Curr Med Chem. 2007;14(11):1263-75. (Pubitemid 46739326)
9. Kohno S, Masaoka T, Yamaguchi H, Mori T, Urabe A, Ito A, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis. 2004;36(5):372-9. (Pubitemid 38967695)
10. Izumikawa K, Ohtsu Y, Kawabata M, Takaya H, Miyamoto A, Sakamoto S, et al. Clinical efficacy of micafungin for chronic pulmonary aspergillosis. Med Mycol. 2007;45(3):273-8. (Pubitemid 46705845)
11. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, Mullane KM, Vazquez J, Anaissie EJ, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis. 2005;24(10):654-61. (Pubitemid 41667052)
12. de Wet NT, Bester AJ, Viljoen JJ, Filho F, Suleiman JM, Ticona E, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther. 2005;21(7):899-907. (Pubitemid 40477250)
13. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45(7):883-93. (Pubitemid 47580382)
14. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: A phase III randomised double-blind trial. Lancet. 2007;369(9572):1519-27. (Pubitemid 46670281)
15. de Wet N, Llanos-Cuentas A, Suleiman J, Baraldi E, Krantz EF, Della Negra M, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis. 2004;39(6):842-9. (Pubitemid 39244300)
16. van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39(10):1407-16. (Pubitemid 39518200)
17. Pettengell K, Mynhardt J, Kluyts T, Lau W, Facklam D, Buell D, et al. Successful treatment of oesophageal candidiasis by micafungin: A novel systemic antifungal agent. Aliment Pharmacol Ther. 2004;20(4):475-81. (Pubitemid 39120260)
18. Sirohi B, Powles RL, Chopra R, Russell N, Byrne JL, Prentice HG, et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;38(1):47-51. (Pubitemid 43923089)
19. Tamura K, Urabe A, Yoshida M, Kanamaru A, Kodera Y, Okamoto S, et al. Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders. Leuk Lymphoma. 2009;50(1): 92-100.
20. Aikawa N, Kusachi S, Oda S, Takesue Y, Tanaka H. Clinical effects of micafungin, a novel echinocandin antifungal agent, on systemic fungal infections in surgery, emergency, and intensivecare medicine: Evaluation using the AKOTT algorithm. J Infect Chemother. 2009;15(4):219-27.
21. Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006;53(5): 337-49. (Pubitemid 44524711)
22. Kubiak DW, Bryar JM, McDonnell AM, Delgado-Flores JO, Mui E, Baden LR, et al. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: A retrospective, observational, sequential cohort analysis. Clin Ther. 2010;32(4):637-48.
23. The Japanese Mycology Study Group, editors. Guidelines for management of deep-seated mycoses 2007. Tokyo: Kyowa Kikaku Ltd.; 2007.
24. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: Clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis. 2008;46:327-60. (Pubitemid 351265310)
25. 3rd European Conference on Infections in Leukemia (homepage on the Internet). Antifungal therapy in leukemia patients 2009 update of the ECIL1 and ECIL 2 Guidelines (updated 2009 September 25-26; cited Juan-Ies-Pins-France). Available from http://www.ichs.org/Resources/Documents/ ECIL%203%20Antifungal%20therapy%20Update%202009.pdf.
26. Maertens J, Marchetti O, Herbrecht R, Cornely OA, Flückiger U, Frêre P, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: Summary of the ECIL 3-2009 Update. Bone Marrow Transplant 2010;1-10.